Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. Juli 2017 11:16 ET | Quelle: Myriad Genetics, Inc.

Myriad to Announce Fiscal Fourth-Quarter 2017 Financial Results on August 8, 2017

SALT LAKE CITY, July 28, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal fourth-quarter 2017 sales and earnings conference call with...
19. Juni 2017 07:05 ET | Quelle: Myriad Genetics, Inc.

Virginia C. Drosos, President of Assurex Health, Receives the EY Entrepreneur of the Year 2017 Award in Ohio Valley Region

SALT LAKE CITY, June 19, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that Virginia (“Gina”) C. Drosos,...
15. Juni 2017 07:05 ET | Quelle: Myriad Genetics, Inc.

Crescendo Bioscience Announces Results from a Meta-Analysis of Studies with Vectra® DA at the 2017 Annual European Congress of Rheumatology

SALT LAKE CITY, June 15, 2017 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data from a meta-analysis of...
08. Juni 2017 07:05 ET | Quelle: Myriad Genetics, Inc.

Crescendo Bioscience Announces Six Studies with Vectra® DA Will Be Presented at the 2017 Annual European Congress of Rheumatology

SALT LAKE CITY, June 08, 2017 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of the Vectra® DA...
04. Juni 2017 07:30 ET | Quelle: Myriad Genetics, Inc.

Myriad’s BRACAnalysis CDx® Test Identified Patients with Metastatic Breast Cancer Who Benefited from Treatment with Olaparib in Phase 3 OlympiAD Study

SALT LAKE CITY, June 04, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its BRACAnalysis...
02. Juni 2017 16:05 ET | Quelle: Myriad Genetics, Inc.

Myriad Announces 17 Additional Health Insurance Plans Covering EndoPredict™

SALT LAKE CITY, June 02, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that multiple new insurance plans...
02. Juni 2017 07:05 ET | Quelle: Myriad Genetics, Inc.

Myriad Genetics Announces Results from a Large 2,000 Patient Clinical Utility Study of Its myRisk® Hereditary Cancer Test at the 53rd Annual Meeting of ASCO

SALT LAKE CITY, June 02, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced results from Study 005, a large...
31. Mai 2017 16:05 ET | Quelle: Myriad Genetics, Inc.

Myriad Genetics to Present at the 2017 William Blair Growth Stock Conference

SALT LAKE CITY, May 31, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and...
30. Mai 2017 16:05 ET | Quelle: Myriad Genetics, Inc.

Myriad Genetics to Present at the 2017 Goldman Sachs Global Healthcare Conference

SALT LAKE CITY, May 30, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone,...
25. Mai 2017 10:37 ET | Quelle: Myriad Genetics, Inc.

Medicare Coverage of Prolaris® Test Expands with the Addition of Men Diagnosed with Favorable Intermediate Risk Prostate Cancer

SALT LAKE CITY, May 25, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that Palmetto GBA, a Medicare...

Vorherige Seite

Nächste Seite